Immunology-oncology ELISA Kits - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The immunology-oncology ELISA kits market size is expected to grow from USD 10.56 billion in 2025 to USD 10.97 billion in 2026 and is forecast to reach USD 13.28 billion by 2031 at 3.9% CAGR over 2026-2031. This report is segmented by Product Type (Direct, Indirect, Others), Detection Technology (Colorimetric, Fluorescent, Chemiluminescent), Application (Disease Diagnosis, Treatment-Response Monitoring, and More), Sample Type (Blood, Tissue, Serum), End User (Hospitals, Diagnostic Centers, and More), and Geography (North America, Europe, Asia-Pacific, MEA, South America). Forecasts in Value (USD).

Global Immunology-oncology ELISA Kits Market Trends and Insights

Immune-Checkpoint Inhibitor Development Broadens the Assay Target Universe

The immunology-oncology ELISA kits market is supported by an immunotherapy pipeline extending beyond PD-1 and CTLA-4 to include LAG-3, TIM-3, and TIGIT. These targets require dedicated soluble protein measurement methods for pharmacodynamic monitoring and translational biomarker research. A 2025 metastatic melanoma study evaluated 7 soluble immune-checkpoint proteins, including sPD-1, sPD-L1, sLAG-3, and sCTLA-4, in 110 patients using commercial ELISA kits, highlighting the value of multi-marker liquid-biopsy panels. Emerging targets can create separate assay categories before related therapies receive regulatory approval, supporting recurring kit demand across clinical research programs.

Companion-Diagnostic and Biomarker Validation Programs Drive Clinical-Grade Kit Adoption

Companion-diagnostic programs require quantitative evidence, increasing the use of validated assay platforms during biomarker development. ELISA kits are commonly used for early biomarker validation before tissue-based diagnostic workflows are finalized. In March 2026, Agilent received its 8th FDA companion diagnostic indication for PD-L1 IHC 22C3 pharmDx for esophageal or gastroesophageal junction carcinoma patients eligible for pembrolizumab. This trend supported demand for clinical-grade ELISA kits with clear performance specifications, reproducible results, and stable supply across study sites.

Absence of Standardized PD-1/PD-L1 Cutoffs Restricts Clinical Decision-Making

The lack of standardized reference ranges for soluble PD-1 and PD-L1 limited the clinical utility of accurate ELISA results. A 2025 study in advanced non-small cell lung cancer reported a hazard ratio of 2.10 for reduced overall survival associated with pretreatment sPD-L1 among pembrolizumab-treated patients. However, the absence of common clinical cutoffs prevented consistent interpretation across institutions and kept much of the testing in research-use-only settings. This gap constrained IVD-grade product adoption, despite their higher revenue per test than research-use alternatives. Interlaboratory studies and alignment on sample handling, calibration, and reporting were required to ensure comparable results. National metrology organizations could support ISO-aligned harmonization, but no consensus had been reached for soluble checkpoint analytes. Consequently, the immunology-oncology ELISA kits market grew through research use, while clinical adoption developed more slowly. Clear clinical thresholds would make routine testing demand more predictable and increase the value of validated kits for diagnostic centers and hospitals.

Other drivers and restraints analyzed in the detailed report include:

• Quantitative Tumor-Microenvironment Profiling Elevates Assay Sensitivity Requirements
• Asia-Pacific Clinical-Trial Expansion Creates Sustained Institutional Procurement
• Multiplex and Molecular Platforms Compress ELISA’s Share in High-Resource Settings

Segment Analysis

Direct ELISA kits held 41.45% of global revenue in 2025. Their single-antibody format reduces procedural steps and limits cross-reactivity risks in serum and plasma workflows. This simplicity supports high-volume hospital laboratories that rely on standardized procedures and consistent sample handling. Indirect ELISA kits are forecast to grow at a CAGR of 4.33% through 2031, supported by signal amplification for low-abundance targets, including sPD-L1, sLAG-3, and sTIM-3.

The Others category includes sandwich and competitive ELISA formats for cytokine quantification and competitive inhibition assays. These formats support applications where analyte concentrations exceed standard calibration limits. In 2025, a study used Proteintech Human PD-1 and PD-L1 sandwich ELISA kits in 55 patients with advanced non-small cell lung cancer receiving pembrolizumab. The kits demonstrated intra-assay coefficients of variation below 7.8% and detection ranges of 0.156-10 ng/mL, reflecting the precision required in clinical research.

Colorimetric ELISA held 36.76% of detection-technology revenue in 2025. The format is compatible with standard 96-well plate readers and familiar laboratory procedures. Its lower cost supports high-throughput screening and laboratories with varying resource levels, particularly in the Asia-Pacific and South America. Chemiluminescent ELISA is forecast to grow at a CAGR of 4.76% through 2031, driven by demand for low-concentration checkpoint protein measurement and immunotherapy monitoring.

Abcam launched SimpleStep Ignite ELISA in April 2026 as a chemiluminescent platform that delivers results in 55 minutes. The company stated that the platform provides 50-fold greater sensitivity and up to a 35-fold wider dynamic range than traditional colorimetric ELISAs. Stricter documentation and performance requirements under the In Vitro Diagnostic Regulation are supporting upgrades to higher-specification systems, although cost and installed equipment continue to sustain demand for colorimetric ELISA.

Complete Report Scope:

• By Product Type
  • Direct ELISA Kits
  • Indirect ELISA Kits
  • Others
• By Detection Technology
  • Colorimetric ELISA
  • Fluorescent ELISA
  • Chemiluminescent ELISA
  • others
• By Application
  • Disease Diagnosis
  • Treatment-response Monitoring
  • Drug Discovery and Development
  • Clinical Research
  • Others
• By Sample Type
  • Blood
  • Tissue
  • Serum
• By End User
  • Hospitals
  • Diagnostic Centers
  • Pharmaceutical and Biotechnology Companies
  • Academic and Government Research Institutes
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held a 40.35% share of the immunology-oncology ELISA kits market in 2025. The region benefits from extensive oncology trials, pharmaceutical research expenditure, and companion diagnostic activity, led by the United States and supported by Canadian academic cancer centers and biobank programs. FDA requirements for validated data in investigational new drug-enabling studies support demand for high-specification kits and create entry barriers for suppliers with consistent lot-to-lot performance. In April 2026, Labcorp launched an FDA-approved companion diagnostic for ovarian cancer to identify patients eligible for KEYTRUDA, marking the first immuno-oncology approval for this indication.

Europe remains a substantial and stable market for immunology-oncology ELISA kits, with Germany, the United Kingdom, and France accounting for a significant share of regional procurement. The In Vitro Diagnostic Regulation increases performance and documentation requirements for IVD products through 2025 and 2026, encouraging laboratories to transition to CE-marked alternatives. This trend consolidates procurement among suppliers with strong compliance documentation and consistent performance data. Italy, Spain, Nordic countries, and Eastern European countries support demand through oncology biomarker studies, expanding immunoassay infrastructure, and ISO 15189-accredited laboratory quality systems.

Asia-Pacific is forecast to grow at a CAGR of 6.25% through 2031, driven by the expansion of China’s tier-one cancer centers and growing regional manufacturing capacity. Japan’s PMDA accelerated review pathways, and India’s CDSCO alignment with the FDA and EMA companion diagnostic validation practices support biomarker-led therapy programs. Demand in the Middle East and Africa is concentrated in Gulf Cooperation Council tertiary hospitals and selected South African oncology centers, while Brazil and Argentina lead the South American market. Cold-chain constraints, institutional funding cycles, and foreign-exchange volatility may moderate growth outside major regional centers.

List of Companies Covered in this Report:

• Abcam
• Arigo Biolaboratories Corp.
• Assay Genie
• Aviva Systems Biology Corporation
• Beckton Dickinson
• Bio-Rad Laboratories
• Bio-Techne
• Boster Biological Technology Co., Ltd.
• Cell Signaling Technology
• Creative Diagnostics
• CUSABIO Technology LLC
• Danaher
• Enzo Biochem, Inc.
• LifeSpan BioSciences, Inc.
• Merck
• OriGene Technologies
• Proteintech Group, Inc.
• RayBiotech Life, Inc.
• Reddot Biotech
• Revvity, Inc.
• Sino Biological, Inc.
• Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support